Reps Challenge FDA On Foreign Drug Monitoring After Recalls

Law360 (February 14, 2019, 6:54 PM EST) -- Lawmakers on both sides of the aisle are questioning the U.S. Food and Drug Administration's ability to inspect foreign drug manufacturers after a series of recalls of foreign-made blood pressure drugs that possibly contained carcinogens, according to a Wednesday letter.

The U.S. House Committee on Energy and Commerce is concerned about a backlog of about 400 foreign pharmaceutical plants that have yet to be inspected by the FDA, after at least 15 recalls of heart pressure drugs made in India and China in the past seven months, according to the letter it sent to FDA commissioner Scott Gottlieb requesting a meeting...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS